Plain-English translation of NCT06869473 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new way to treat advanced head and neck cancer by using a specific combination of chemotherapy drugs followed by a medication called Avelumab. The study aims to see if this approach—starting with chemotherapy and then moving to immunotherapy—works better than standard treatments, especially for patients whose tumors have a certain protein marker (PD-L1) at intermediate levels.
Currently, newer immunotherapy drugs work very well for some head and neck cancer patients but not as well for others, particularly those with intermediate PD-L1 levels. This trial is exploring whether a different treatment sequence—using chemotherapy first, then immunotherapy—could help this group of patients who haven't yet benefited from existing options.
You likely qualify if…
You likely don't qualify if…
You would first receive three cycles of chemotherapy combined with the targeted drug Cetuximab as your initial treatment. If your cancer responds well or remains stable, you would then continue with maintenance therapy using Avelumab and Cetuximab until your disease progresses, side effects become too difficult to manage, or you decide to stop. You will have regular visits for blood work, scans, and physical exams to monitor how well the treatment is working and how you're tolerating it.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Italy